Pancreatic Cancer Research

ResearcherTongji HospitalNo recent work listed

Ruizhi He

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-3998-3836; OpenAlex author ID A5037280476. Sources: OpenAlex.

Their work

Papers
16 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
33
Papers, trials and grants by year

2016: 2 papers · 2017: none · 2018: 6 papers · 2019: 4 papers · 2020: 1 paper · 2021: 2 papers · 2022: 1 paper

Papers 16

  1. Hypoxia activated HGF expression in pancreatic stellate cells confers resistance of pancreatic cancer cells to EGFR inhibition. Co-author DOI 10.1016/j.ebiom.2022.104352↗
  2. Long Noncoding Competing Endogenous RNA Networks in Pancreatic Cancer. Co-author DOI 10.3389/fonc.2021.765216↗
  3. Inhibition of PI3K/AKT signaling via ROS regulation is involved in Rhein-induced apoptosis and enhancement of oxaliplatin sensitivity in pancreatic cancer cell… Co-author DOI 10.7150/ijbs.49514↗
  4. Upregulation of METTL14 mediates the elevation of PERP mRNA N6 adenosine methylation promoting the growth and metastasis of pancreatic cancer. Co-author DOI 10.1186/s12943-020-01249-8↗
  5. Danthron suppresses autophagy and sensitizes pancreatic cancer cells to doxorubicin. Co-author DOI 10.1016/j.tiv.2018.10.019↗
  6. Long noncoding RNA LINC01111 suppresses pancreatic cancer aggressiveness by regulating DUSP1 expression via microRNA-3924. Co-author DOI 10.1038/s41419-019-2123-y↗
  7. TFEB-driven autophagy potentiates TGF-β induced migration in pancreatic cancer cells. Co-author DOI 10.1186/s13046-019-1343-4↗
  8. PINK1/Parkin-Mediated Mitophagy Regulation by Reactive Oxygen Species Alleviates Rocaglamide A-Induced Apoptosis in Pancreatic Cancer Cells. First author DOI 10.3389/fphar.2019.00968↗
  9. Alantolactone induces apoptosis and improves chemosensitivity of pancreatic cancer cells by impairment of autophagy-lysosome pathway via targeting TFEB. Co-author DOI 10.1016/j.taap.2018.08.003↗
  10. A Five-microRNA Signature for Survival Prognosis in Pancreatic Adenocarcinoma based on TCGA Data. Co-author DOI 10.1038/s41598-018-22493-5↗
  11. Meta-analysis on resected pancreatic cancer: a comparison between adjuvant treatments and gemcitabine alone. First author DOI 10.1186/s12885-018-4948-7↗
  12. Regulatory B cells induced by pancreatic cancer cell-derived interleukin-18 promote immune tolerance via the PD-1/PD-L1 pathway. Co-author DOI 10.18632/oncotarget.22976↗
  13. Three-lncRNA signature is a potential prognostic biomarker for pancreatic adenocarcinoma. Co-author DOI 10.18632/oncotarget.24443↗
  14. Combined inhibition of autophagy and Nrf2 signaling augments bortezomib-induced apoptosis by increasing ROS production and ER stress in pancreatic cancer cells. Co-author DOI 10.7150/ijbs.26776↗
  15. Par3 regulates invasion of pancreatic cancer cells via interaction with Tiam1. Co-author DOI 10.1007/s10238-015-0365-2↗
  16. Blocking NF-κB Is Essential for the Immunotherapeutic Effect of Recombinant IL18 in Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-15-1144↗

Closest collaborators

The 25 strongest of 33 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Renyi Qin · 15 shared papers, 2016–2022 · strength 1.29
  2. Min Wang · 13 shared papers, 2016–2022 · strength 1.11
  3. Xingjun Guo · 12 shared papers, 2016–2022 · strength 0.95
  4. Shutao Pan · 9 shared papers, 2018–2022 · strength 0.84
  5. Xiuhui Shi · 9 shared papers, 2018–2022 · strength 0.80
  6. Chunle Zhao · 8 shared papers, 2018–2022 · strength 0.75
  7. Yan Zhao · 9 shared papers, 2016–2022 · strength 0.67
  8. Yuhui Liu · 5 shared papers, 2019–2022 · strength 0.50
  9. Li Xu · 5 shared papers, 2019–2021 · strength 0.49
  10. Min Zhou · 6 shared papers, 2018–2019 · strength 0.49
  11. Min Zhou · 4 shared papers, 2018–2022 · strength 0.41
  12. Xu Li · 4 shared papers, 2016–2022 · strength 0.31
  13. Chengjian Shi · 4 shared papers, 2016–2021 · strength 0.29
  14. Jianxin Jiang · 4 shared papers, 2016–2020 · strength 0.25
  15. Taoyuan Yin · 2 shared papers, 2019–2022 · strength 0.22
  16. Hua Chen · 2 shared papers, 2019 · strength 0.19
  17. Hua Chen · 2 shared papers, 2018–2019 · strength 0.17
  18. Shuo Yu · 2 shared papers, 2018–2020 · strength 0.16
  19. Xiaodong Xu · 2 shared papers, 2016–2020 · strength 0.13
  20. Guangbing Xiong · 1 shared paper, 2021 · strength 0.12
  21. Jikuan Jin · 1 shared paper, 2021 · strength 0.12
  22. Yuqing Zhang · 1 shared paper, 2022 · strength 0.12
  23. Min Li · 1 shared paper, 2022 · strength 0.12
  24. Zhijun Zhou · 1 shared paper, 2022 · strength 0.12
  25. Jingxuan Yang · 1 shared paper, 2022 · strength 0.12

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.